Differential expression of p42.3 in low- and high-grade gliomas
- Equal contributors
1 Department of Neurosurgery, Beijing Tiantan Hospital Capital Medical University, No.6 Tiantan Xili, Dongcheng District, 100050 Beijing, People’s Republic of China
2 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital/Institute, No. 52 Fucheng Road, Haidian District, 100142 Beijing, People’s Republic of China
3 Neuro-Pathology Department, Beijing Neurosurgical Institute, No.6 Tiantan Xili, Dongcheng District, 100050 Beijing, People’s Republic of China
World Journal of Surgical Oncology 2014, 12:185 doi:10.1186/1477-7819-12-185Published: 14 June 2014
Malignant gliomas are the most common form of primary malignant brain tumor. It has recently been suggested that genetic changes are involved in the progression of malignant gliomas. In previous studies, a novel gene, p42.3, was characterized as a tumor-specific gene that encodes a mitosis phase–dependent expression protein which is expressed in gastric cancer, but not in matched normal tissues.
In a series of 200 human brain gliomas and 13 normal tissues, we performed RT-PCR and mRNA in situ hybridization for analysis of p42.3 gene expression in gliomas, including astrocytoma (grade 2), oligoastrocytomas (grade 2), anaplastic oligoastrocytomas (grade 3), glioblastomas (grade 4) and normal tissues. Also, the mRNA expression was detected in gliomas by in situ hybridization. After producing polyclonal antibody to p42.3, we further tested p42.3 protein expression in astrocytomas and glioblastomas by immunohistochemistry and Western blot analysis.
Our results demonstrated that overexpression of the p42.3 gene is detected in gliomas, but not in normal brain tissues. Importantly, p42.3 mRNA expression is correlated with the pathological features of gliomas. In addition, p42.3 protein is expressed in both the cytoplasm and the nucleus in astrocytomas, whereas this protein appeared in the cytoplasm in glioblastomas.
These results indicate that p42.3 might be involved in carcinogenesis as a potential molecular marker for malignant gliomas.